Company news
ImmunityBio, Inc. news in 2023
ImmunityBio, Inc.'s news releases, calls and decks from 2023, newest first.
ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference
November 15, 2023
First Data for ImmunityBio’s Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity
November 6, 2023
FDA Accepts ImmunityBio’s BLA Resubmission as Complete and Sets New PDUFA Date
October 25, 2023
ImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ
October 22, 2023
ImmunityBio Announces $470 Million Equity and Debt Financing From Founder, Dr. Patrick Soon-Shiong and Nant Entities
September 10, 2023
ImmunityBio Names Enrique Diloné as Chief Technology Officer
August 2, 2023
ImmunityBio Announces Execution of $40 Million Equity Financing with Institutional Investors
July 19, 2023
ImmunityBio to Participate in the Jefferies Global Healthcare Conference
May 21, 2023
National Multicenter Trial Opens to Study ImmunityBio’s Tri-Ad5 Cancer Vaccines Plus N-803 to Prevent Cancer in People with Lynch Syndrome
April 24, 2023
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong Delivers the Packard Lecture at Uniformed Services University
April 23, 2023
ImmunityBio to Present ‘Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15R⍺Fc superagonist N-803 plus BCG’ at ASCO GU
February 15, 2023
ImmunityBio Announces Execution of $50 Million Equity Financing with Multiple Institutional Investors
February 14, 2023
ImmunityBio Announces Presentation at ASCO GI 2023 of Fully Enrolled Trial in Third-Line and Greater Pancreatic Cancer and Update on FDA Type B Meetings Regarding Paths to Registration
January 18, 2023